News

5b16c2daa31001b8b9ba0350

Chinese fund invests in British surgical robot

By Angus McNeice | chinadaily.com.cn | Updated: 2018-06-06 01:05 A British company that has developed a robot that performs surgery has raised $100 million in funding from five investors including the Zhejiang SilkRoad Fund in China. Cambridge-based…
novocure-7x4

Novocure brings Optune tech to drug trial for glioblastoma

Novocure (NSDQ:NVCR) said today that it joined a Phase Ib study to evaluate the safety of Celgene‘s (NSDQ:CELG) marizomib and temozolomide in combination with Optune for patients with newly-diagnosed glioblastoma. The trial is the first…
BrendanFrey2_DeepGenomics_credit-Johnny-Guatto_600x400

Deep Genomics Shifts Focus to Genetic Medicines

By Allison Proffitt  May 12, 2017 | In August 2015 when Deep Genomics first launched, co-founder Brendan Frey made a prediction. “There’s a sea change coming,” he told Bio-IT World. “People are going to be focusing now on the machine…
Tencent Holdings Ltd.'s new headquarters stand under construction in Shenzhen, China, on Monday, Aug. 22, 2016. The new headquarters for Tencent is a $599 million project aimed at creating a campus-like atmosphere for the urban setting. Scheduled for completion next year, the Shenzhen skyscraper could become one of the largest labs for new internet services and connected devices. Photographer: Qilai Shen/Bloomberg via Getty Images

Tencent increases its focus on artificial intelligence

When it comes to artificial intelligence (AI) and Chinese tech companies, thoughts often begin and end with Baidu. But Tencent, Asia’s second highest-valued tech company behind Alibaba, has reminded the world that it too is investing in the…
editas

Editas, Allergan Ink $90M CRISPR-Based Eye Drug Deal

NEW YORK (GenomeWeb) – Editas Medicine has signed a deal potentially worth more than $90 million, giving Allergan the exclusive rights to license certain of its CRISPR genome editing-based treatments for eye diseases. Under the terms of…
freenome

Freenome Raises $65M in Series A Funds

NEW YORK (GenomeWeb) – Palo Alto, California-based Freenome announced today that it has raised $65 million in Series A funding, which it will put toward conducting clinical trials to validate its non-invasive, early cancer detection technology. The…
26CHIMERA3-superJumbo-v2

New prospects for growing human replacement organs in animals

For the first time, biologists have succeeded in growing human stem cells in animal embryos, shifting from science fiction to the realm of the possible the idea of developing human organs in animals for later transplant. The approach involves…